These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31790980)

  • 1. Is it feasible to pay specialty substance use disorder treatment programs based on patient outcomes?
    Hodgkin D; Garnick DW; Horgan CM; Busch AB; Stewart MT; Reif S
    Drug Alcohol Depend; 2020 Jan; 206():107735. PubMed ID: 31790980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public policy, attitudes and willingness to pay for treatment of substance dependence in Iran.
    Ahmadian Moghaddam S; Mazyaki A; Razaghi EM
    Int J Drug Policy; 2019 Dec; 74():84-89. PubMed ID: 31585318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and impact of bundled payment for detox and follow-up care.
    Quinn AE; Hodgkin D; Perloff JN; Stewart MT; Brolin M; Lane N; Horgan CM
    J Subst Abuse Treat; 2017 Nov; 82():113-121. PubMed ID: 29021109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal association of preference-weighted health-related quality of life measures and substance use disorder outcomes.
    Pyne JM; Tripathi S; French M; McCollister K; Rapp RC; Booth BM
    Addiction; 2011 Mar; 106(3):507-15. PubMed ID: 21205046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are Improvements in Measured Performance Driven by Better Treatment or "Denominator Management"?
    Harris AH; Chen C; Rubinsky AD; Hoggatt KJ; Neuman M; Vanneman ME
    J Gen Intern Med; 2016 Apr; 31 Suppl 1(Suppl 1):21-7. PubMed ID: 26951270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State parity laws and access to treatment for substance use disorder in the United States: implications for federal parity legislation.
    Wen H; Cummings JR; Hockenberry JM; Gaydos LM; Druss BG
    JAMA Psychiatry; 2013 Dec; 70(12):1355-62. PubMed ID: 24154931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of accountable care and payment reform on substance use disorder treatment: evidence from the initial 3 years of the alternative quality contract.
    Stuart EA; Barry CL; Donohue JM; Greenfield SF; Duckworth K; Song Z; Mechanic R; Kouri EM; Ebnesajjad C; Chernew ME; Huskamp HA
    Addiction; 2017 Jan; 112(1):124-133. PubMed ID: 27517740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Directed funding to address under-provision of treatment for substance use disorders: a quantitative study.
    Frakt AB; Trafton J; Wallace A; Neuman M; Pizer S
    Implement Sci; 2013 Jul; 8():79. PubMed ID: 23866119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of onsite versus referral primary medical care for veterans in addictions treatment.
    Saxon AJ; Malte CA; Sloan KL; Baer JS; Calsyn DA; Nichol P; Chapko MK; Kivlahan DR
    Med Care; 2006 Apr; 44(4):334-42. PubMed ID: 16565634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth in spending on substance use disorder treatment services for the privately insured population.
    Thomas CP; Hodgkin D; Levit K; Mark TL
    Drug Alcohol Depend; 2016 Mar; 160():143-50. PubMed ID: 26781063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the treatment identification strategy of the HEDIS addiction quality measures: concordance with medical record review.
    Harris AH; Reeder RN; Ellerbe LS; Bowe TR
    BMC Health Serv Res; 2011 Apr; 11():73. PubMed ID: 21481264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The response of substance use disorder treatment providers to changes in macroeconomic conditions.
    Cantor J; Stoller KB; Saloner B
    J Subst Abuse Treat; 2017 Oct; 81():59-65. PubMed ID: 28847456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Alternative Payment and Delivery Models With Outcomes for Mental Health and Substance Use Disorders: A Systematic Review.
    Carlo AD; Benson NM; Chu F; Busch AB
    JAMA Netw Open; 2020 Jul; 3(7):e207401. PubMed ID: 32701157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substance Use Disorder Treatment Services for Women in the Veterans Health Administration.
    Timko C; Hoggatt KJ; Wu FM; Tjemsland A; Cucciare M; Rubin A; Simpson TL
    Womens Health Issues; 2017; 27(6):639-645. PubMed ID: 28602581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recovery schools for improving behavioral and academic outcomes among students in recovery from substance use disorders: a systematic review.
    Hennessy EA; Tanner-Smith EE; Finch AJ; Sathe N; Kugley S
    Campbell Syst Rev; 2018; 14(1):1-86. PubMed ID: 37131375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining trends in substance use disorder capacity and service delivery by Health Resources and Services Administration-funded health centers: A time series regression analysis.
    Pourat N; O'Masta B; Chen X; Lu C; Zhou W; Daniel M; Hoang H; Sripipatana A
    PLoS One; 2020; 15(11):e0242407. PubMed ID: 33253263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between patient experience and clinical outcomes in substance use disorder clinics: Findings from the veterans outcomes assessment survey.
    Liebmann EP; Resnick SG; Hoff RA; Katz IR
    J Subst Abuse Treat; 2022 Feb; 133():108505. PubMed ID: 34148757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preference-weighted health-related quality of life measures and substance use disorder severity.
    Pyne JM; French M; McCollister K; Tripathi S; Rapp R; Booth B
    Addiction; 2008 Aug; 103(8):1320-9; discussion 1330-2. PubMed ID: 18397359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of paying treatment providers for outcomes: difference-in-differences analysis of the 'payment by results for drugs recovery' pilot.
    Mason T; Sutton M; Whittaker W; McSweeney T; Millar T; Donmall M; Jones A; Pierce M
    Addiction; 2015 Jul; 110(7):1120-8. PubMed ID: 26058447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States.
    Abraham AJ; Knudsen HK; Rieckmann T; Roman PM
    J Stud Alcohol Drugs; 2013 Mar; 74(2):258-65. PubMed ID: 23384373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.